Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2007

View Archived Issues

Davanat progress updates

TB Alliance supports initiatives in tuberculosis treatment development

Recent patents disclose new agents for treating neurological disorders

Positive phase Ib/II data for PBI-402 in anemia prompts ProMetic to file trial expansion

Actemra improves RA symptoms in latest phase III trial

Oleoyl-estrone discontinued for common obesity and morbid obesity

Akesis files pre-IND for AKP-020

Noven to acquire JDS Pharmaceuticals

Pieris validates pulmonary delivery of Anticalin candidate

AnGes updates phase II study of NF-kappaB decoy oligodeoxynucleotide

Data on apixaban safety and antithrombotic activity accumulate

Ixabepilone demonstrates activity in phase II metastatic breast cancer studies

DUET studies show efficacy of TMC-125 in previously treated HIV patients

Daichii Sankyo profiles novel FXa inhibitor

Novel cholesteryl ester transfer protein inhibitors reported by Lilly

Recent patents describe new agents targeting cardiovascular diseases

FGF-1 approved for phase II trial in coronary heart disease

Protox reports positive data from PRX-302 phase I clinical trial in prostate cancer

Novel cathepsin C inhibitors presented at the AFMC meeting

Genaera grants option to license pexiganan to MacroChem

Positive results for Theravance's TD-1792 for treatment of cSSSI

Depomed reports results of Gabapentin GR phase III trial

Carbaglu granted fast track designation for NAGS deficiency

sNDA planned for Tygacil in community-acquired pneumonia

Recent patents report novel therapeutic agents for dermatological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...